Technology
Health
Biotechnology

Affimed

$4.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (3.58%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Affimed and other stocks, options, ETFs, and crypto commission-free!

About

Affimed N.V., also called Affimed, is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. Read More The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Employees
61
Headquarters
Heidelberg, Baden Wuerttemberg
Founded
2000
Market Cap
261.57M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
965.60K
High Today
$4.68
Low Today
$4.02
Open Price
$4.22
Volume
1.13M
52 Week High
$7.35
52 Week Low
$1.40

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2014 IPO

News

Markets Insider16h

Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019

Heidelberg, Germany, March 20, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it will host a conference call on Wednesday, March 27, 2019 at 8:30 a.m. ET to discuss its full year 2018 financial results and corporate developments. The conference call will be available via phone and webcast. To access the call, please dial +1 631 510 7495 for U.S. callers, or +44 (0) 2071 928000 fo...

64
Seeking AlphaMar 19

Affimed up 9% premarket on milestone payment

Affimed N.V. (NASDAQ:AFMD) will receive a payment in an undisclosed amount on achieving preclinical milestone under its ongoing strategic collaboration with Genentech, a member of the Roche Group.

43
Associated PressMar 19

Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.  Heidelberg, Germany, March 19, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that the Company will re...

32

Earnings

-$0.23
-$0.20
-$0.18
-$0.15
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.18 per share
Actual
Expected Mar 26, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.